Mainstream

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Post ContentalnyRead More

You might also be interested in reading Optimism Foundation Sends 20M Tokens To The Wrong Wallet.

February 14, 2025
In Mainstream